Molecular Imaging of Somatostatin Receptors with 68Ga-DOTATOC-PET in Patients with Meningioma Abstract #851

Introduction: In vitro studies showed that meningioma cells may express somatostatin receptors (SSTRs), which bears the possibility of receptor-mediated radionuclide therapy in patients with meningioma.
Aim(s): To evaluate the application of 68Ga-DOTATOC-PET in patients with meningioma and the correlation between the expression of SSTRs in meningioma and gender, age of patients and tumor size.
Materials and methods: Twenty-five patients (14 f, 11 m; age 22-80 years) with meningioma were investigated with 68Ga-DOTATOC-PET (150 MBq, i.v.). Software-based coregistration of PET with MRI and/or CT was performed using Hybrid Viewer from Hermes Medical Solutions. Expression of SSTRs was classified in 4 grades [0, no uptake; 1, faint uptake; 2, moderate uptake; 3, high uptake (equal or higher than pituitary uptake)]. The tumor size (range 0.7-6.0 cm) was established on recent (< 48 hr) MRI and/or CT data.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Prof. Dr. Margarida Rodrigues

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1909 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients treated with First Full PRRT
Introduction: Only few studies have correlated 18F-FDG and SSTR imaging with NET grade.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Prof.Dr. Margarida Rodrigues
Keywords: 68Ga-PET, FDG
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Paola Mapelli
#315 The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Andrea Frilling
#2973 Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of malignancies with varied histology, localization and behaviour.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Virginia Liberini